Switch theme
Sign up to access all valuation multiples
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
2000
575
LTM Revenue $156M
LTM EBITDA -$254M
$676M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Pacific Biosciences has a last 12-month revenue of $156M and a last 12-month EBITDA of -$254M.
In the most recent fiscal year, Pacific Biosciences achieved revenue of $154M and an EBITDA of -$243M.
Pacific Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Pacific Biosciences valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $201M | $154M | XXX | XXX | XXX |
| Gross Profit | $49.0M | $52.8M | XXX | XXX | XXX |
| Gross Margin | 24% | 34% | XXX | XXX | XXX |
| EBITDA | -$277M | -$243M | XXX | XXX | XXX |
| EBITDA Margin | -138% | -158% | XXX | XXX | XXX |
| Net Profit | -$314M | -$307M | XXX | XXX | XXX |
| Net Margin | -157% | -199% | XXX | XXX | XXX |
| Net Debt | $573M | $713M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Pacific Biosciences's stock price is $1.
Pacific Biosciences has current market cap of $393M, and EV of $676M.
See Pacific Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $676M | $393M | XXX | XXX | XXX | XXX | $-1.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Pacific Biosciences has market cap of $393M and EV of $676M.
Pacific Biosciences's trades at 4.3x LTM EV/Revenue multiple, and -2.7x LTM EBITDA.
Analysts estimate Pacific Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Pacific Biosciences and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $676M | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | XXX | XXX |
| EV/EBITDA | -2.8x | XXX | XXX | XXX |
| P/E | -1.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -3.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPacific Biosciences's NTM/LTM revenue growth is 10%
Pacific Biosciences's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.6M for the same period.
Over next 12 months, Pacific Biosciences's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Pacific Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Pacific Biosciences and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -23% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -158% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -12% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -148% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 88% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 213% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Pacific Biosciences acquired XXX companies to date.
Last acquisition by Pacific Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Pacific Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Pacific Biosciences founded? | Pacific Biosciences was founded in 2000. |
| Where is Pacific Biosciences headquartered? | Pacific Biosciences is headquartered in United States of America. |
| How many employees does Pacific Biosciences have? | As of today, Pacific Biosciences has 575 employees. |
| Who is the CEO of Pacific Biosciences? | Pacific Biosciences's CEO is Mr. Christian O. Henry. |
| Is Pacific Biosciences publicy listed? | Yes, Pacific Biosciences is a public company listed on NAS. |
| What is the stock symbol of Pacific Biosciences? | Pacific Biosciences trades under PACB ticker. |
| When did Pacific Biosciences go public? | Pacific Biosciences went public in 2010. |
| Who are competitors of Pacific Biosciences? | Similar companies to Pacific Biosciences include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Pacific Biosciences? | Pacific Biosciences's current market cap is $393M |
| What is the current revenue of Pacific Biosciences? | Pacific Biosciences's last 12-month revenue is $156M. |
| What is the current EBITDA of Pacific Biosciences? | Pacific Biosciences's last 12-month EBITDA is -$254M. |
| What is the current EV/Revenue multiple of Pacific Biosciences? | Current revenue multiple of Pacific Biosciences is 4.3x. |
| What is the current EV/EBITDA multiple of Pacific Biosciences? | Current EBITDA multiple of Pacific Biosciences is -2.7x. |
| What is the current revenue growth of Pacific Biosciences? | Pacific Biosciences revenue growth between 2023 and 2024 was -23%. |
| Is Pacific Biosciences profitable? | Yes, Pacific Biosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
